Program Description
Event Details
A Medical Food that Revitalizes Sulphonylurea for the Treatment of Type 2 Diabetes
Type 2 diabetes mellitus has become a major global health crisis. The number of diagnosed patients in a country accounts for ~8% of its population. The currently marketed anti-diabetes drugs generally have major side effects and limited efficacy, necessitating multiple drugs to control most patient’s glycemia. Thus, treatment for diabetes is often inadequate and poses major challenges. GlyConMedics team is dedicated to develop a new adjunctive treatment, a proprietary prebiotic, to wide ly prescribed and cost-effective sulfonylurea anti-diabetes drugs, to significantly reduce sulfonylurea’s major si de effects, and to extend duration and strength of its effectiveness.